# RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)

> **NCT05134012** · PHASE3 · RECRUITING · sponsor: **MedTrace Pharma A/S** · enrollment: 215 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **DRUG:** [O-15]-Water PET Myocardial Perfusion Imaging (MPI)

## Key facts

- **NCT ID:** NCT05134012
- **Lead sponsor:** MedTrace Pharma A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-05-08
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-12-31
- **Target enrollment:** 215 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05134012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05134012, "RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05134012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*